Global leader in antibody-based therapeutics
The Danish biotech company Genmab is a global leader in the development of innovative antibody-based therapeutics for cancer treatment and other serious diseases.
For 25 years, they have heavily invested in innovation and drug development, leading to eight antibody-based medications on the market.
Developing antibody-based drugs using artificial intelligence
Associate Professor Victor Greiff, along with researcher Fridtjof Lund-Johansen from Oslo University Hospital, have established a pipeline where advanced biotechnology is combined with artificial intelligence to develop antibody-based therapeutics. The collaboration with Genmab provides new opportunities for the development of this technology to an industrial scale.
This partnership will span over four years and will notably include funding for several research positions within the project. Both Greiff and Lund-Johansen are co-leads on the project.
The Norwegian researchers are proud to have secured a collaboration with Genmab.
"The project is at the core of our research field. This is research and development we would have pursued anyway, but this agreement significantly accelerates our progress," Greiff says.
A win-win for both parties
Deputy Head at the Institute of Clinical Medicine, Shuo-Wang Qiao, is very pleased with the new collaboration.
"Our researchers gain access to large amounts of data generated from laboratories equipped with industry-scale instruments, which they can use to train their AI model for antibody structure. Genmab gets assistance in interpreting these massive datasets. It’s a win-win situation for both parties and an exciting form of collaboration," she says.
Leading researchers in their field
Greiff leads a research group, GreiffLab, at the Department of Immunology at the University of Oslo and was awarded a Consolidator Grant from the European Research Council (ERC) in 2023.
Fridtjof Lund-Johansen is a PI at Precision Immunotherapy Alliance (PRIMA), a Norwegian Centre of Excellence.
Read more on Inven2's webpage.